Teva Pharmaceuticals’ collaboration with Intel this week to develop a way to track Huntington’s disease patients through a combined platform of wearables and machine learning platform is a fascinating development. The partnership underscores the pharma industry’s growing interest in using digital health to develop a more complete understanding of patient populations to advance drug development. Neurodegenerative diseases represent a particularly interesting area for wearables to come into play as clinicians and researchers seek to better understand disease progression.
